Skip to main content
Premium Trial:

Request an Annual Quote

Waters' Fiscal Q2 Revenue Up 17 Percent as R&D Slides and Profit Jumps 25 Percent

NEW YORK (GenomeWeb News) — Waters today said its fiscal second-quarter revenue climbed 17 percent and its net income grew by 25 percent.
Total revenue for the three months ended June 30 rose to $353 million from $302 million year over year.
Waters CEO Douglas Berthiaume said the company’s “generally broad-based” first-quarter growth sped up in the second quarter, “with continued rapid uptake of our new products and strengthening demand from life science customers, including our large pharmaceutical accounts.”
Berthiaume also called the first half of 2007 “very encouraging.”
R&D spending slid 3 percent to $19.1 million from $19.7 million in the prior-year period.
Net income grew to $59.9 million from $47.8 million year over year.
As of June 30, Waters had $544.3 million in cash and cash equivalents.

The Scan

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.

Coronary Artery Disease Risk Loci, Candidate Genes Identified in GWAS Meta-Analysis

A GWAS in Nature Genetics of nearly 1.4 million coronary artery disease cases and controls focused in on more than 200 candidate causal genes, including the cell motility-related myosin gene MYO9B.

Multiple Sclerosis Contributors Found in Proteome-Wide Association Study

With a combination of genome-wide association and brain proteome data, researchers in the Annals of Clinical and Translational Neurology tracked down dozens of potential multiple sclerosis risk proteins.

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.